Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Vicaut

Showing results (1-10 of 522) with videos related to

Pageof 53
Sort By:
Presse Medicale (Paris, France : 1983)|February 10, 2007
[Noninferiority trials: several simple principles]Eric Vicaut, Michel Cucherat
Arthritis & Rheumatology (Hoboken, N.J.)|October 9, 2022
ReplyPatricia Senet, Eric Vicaut,
Presse Medicale (Paris, France : 1983)|March 20, 2008
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?]Stanislas Chaussade, Bernard Avouac, Eric Vicaut
Epilepsia|December 3, 2010
Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathwaysAngélique Régnier, Eric Vicaut, Sima Mraovitch
The New England Journal of Medicine|January 3, 2025
Beta-Blockers after Myocardial Infarction. ReplyJohanne Silvain, Eric Vicaut, Gilles Montalescot
American Journal of Physiology. Heart and Circulatory Physiology|December 7, 2007
In vivo reactive oxygen species production induced by ischemia in muscle arterioles of mice: involvement of xanthine oxidase and mitochondriaNathalie Baudry, Elisabeth Laemmel, Eric Vicaut
Presse Medicale (Paris, France : 1983)|November 3, 2006
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?]Stanislas Chaussade, Bernard Avouac, Eric Vicaut
Clinical and Experimental Rheumatology|October 18, 2016
Abortion of the UVEXATE study: are we unable to evaluate cheap and well-tolerated treatments?François Rodrigues, Eric Vicaut, Sébastien Abad
The New England Journal of Medicine|August 8, 2014
Fibrinolysis for intermediate-risk pulmonary embolismGuy Meyer, Eric Vicaut, Stavros V Konstantinides
The New England Journal of Medicine|March 1, 2013
Bedside monitoring of antiplatelet therapy for coronary stentingGilles Montalescot, Eric Vicaut, Jean-Philippe Collet
Pageof 53

Showing results (1-10 of 522) with videos related to

Sort By:
Pageof 53
Presse Medicale (Paris, France : 1983)|February 10, 2007
[Noninferiority trials: several simple principles]Eric Vicaut, Michel Cucherat
Arthritis & Rheumatology (Hoboken, N.J.)|October 9, 2022
ReplyPatricia Senet, Eric Vicaut,
Presse Medicale (Paris, France : 1983)|March 20, 2008
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?]Stanislas Chaussade, Bernard Avouac, Eric Vicaut
Epilepsia|December 3, 2010
Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathwaysAngélique Régnier, Eric Vicaut, Sima Mraovitch
The New England Journal of Medicine|January 3, 2025
Beta-Blockers after Myocardial Infarction. ReplyJohanne Silvain, Eric Vicaut, Gilles Montalescot
American Journal of Physiology. Heart and Circulatory Physiology|December 7, 2007
In vivo reactive oxygen species production induced by ischemia in muscle arterioles of mice: involvement of xanthine oxidase and mitochondriaNathalie Baudry, Elisabeth Laemmel, Eric Vicaut
Presse Medicale (Paris, France : 1983)|November 3, 2006
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?]Stanislas Chaussade, Bernard Avouac, Eric Vicaut
Clinical and Experimental Rheumatology|October 18, 2016
Abortion of the UVEXATE study: are we unable to evaluate cheap and well-tolerated treatments?François Rodrigues, Eric Vicaut, Sébastien Abad
The New England Journal of Medicine|August 8, 2014
Fibrinolysis for intermediate-risk pulmonary embolismGuy Meyer, Eric Vicaut, Stavros V Konstantinides
The New England Journal of Medicine|March 1, 2013
Bedside monitoring of antiplatelet therapy for coronary stentingGilles Montalescot, Eric Vicaut, Jean-Philippe Collet
Pageof 53